The Role of Genetic Polymorphism in the Formation of Arterial Hypertension, Type 2 Diabetes and their Comorbidity

Shalimova, Anna; Фадєєнко, Г. Д.; Kolesnikova, Olena; Isayeva, Ganna; Zlatkina, Vira; Nemtsova, Valeriya; Prosolenko, Kostyantyn; Psarova, Valentyna Hryhorivna; Kyrychenko, N.; Kochuieva, Maryna

doi:10.2174/1381612825666190314124049

Cited by 12 publications

(7 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding carbohydrate metabolism disorders in NAFLD, our data are the same as those obtained in recent studies [17]. The data of our study confirm the influence of the G276T polymorphism of the ADIPOQ gene on biochemical parameters in patients with NAFLD and AH [10,14,15].…”

Section: Table 3 Comparative Evaluation Of Metabolic Parameters Of Patients With Comorbidity Of Nafld and Rpah In G/g And G/t + T/t Genotsupporting

confidence: 90%

Contribution of adipoq genetic polymorphism to the formation and course of comorbidity of non-alcoholic fatty liver disease and renoparinchemal arterial hypertension

Babak

Prosolenko

Панченко

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction. Nowadays nonalcoholic fatty liver disease (NAFLD) consider as multisystem disease that is primarily associated with components of the metabolic syndrome and is associated with cardiovascular and renal impairment. The comorbidity of NAFLD with renoparenchymal arterial hypertension (RPAH) has not been sufficiently studied. The purpose of the study was to investigate the influence of G276T genetic polymorphism of ADIPOQ on the severity of metabolic disorders, inflammation, liver, artery and kidney damage in the comorbidity of NAFLD and RPAH. Materials and methods. The study included 87 patients with comorbidity of NAFLD and RPAH, grade 2. The mean age of patients was 50.78 ± 9.35 years. The vast majority of patients were overweight or obese. The control group was composed of 20 healthy volunteers. Parameters of carbohydrate and lipid metabolism, liver and kidney’s function, adiponectin, fetuin-A, cytokeratin-18, pro-inflammatory cytokines levels were investigated. For diagnostic of non-alcoholic steatosis and indication parameters of arteries, an ultrasound method was used. Results. It was found that the T allele was detected in 62 (35.6%) patients of the main group, which was significantly (p<0,05) different from the control group (22.5%). In the presence of patients with comorbidity NAFLD and RPAH G/T and T/T genotypes, carbohydrate metabolism disorders are more pronounced than in the G/G genotype. Thus, index HOMA in this group was 4.52 ± 0.87, which was significantly higher than patients with G/G genotype - 3.77 ± 0.53 (p <0.01).The G276T polymorphism of the ADIPOQ is not associated with markers of liver and kidney damage in patients with NAFLD + RPAH. The presence of G/T and T/T genotypes in patients with comorbidity of NAFLD and RPAH is associated with an increase in interleukin-6 and fetuin-A compared to the G/G genotype. Patients with comorbidity of NAFLD + RPAH and with the T allele of the polymorphic marker G276T of the ADIPOQ gene are more likely to have impaired endothelium-dependent vasodilation, indicating more significant vascular reactivity disorders - 7.72 ± 1.25% for the genotype G/G, and 7.00 ± 1.10% for the genotype G/T (p <0,01). Conclusions. The presence of the T allele of the polymorphic marker G276T of the ADIPOQ is associated with the development of comorbidity of NAFLD and RPAH.

show abstract

Section: Table 3 Comparative Evaluation Of Metabolic Parameters Of Patients With Comorbidity Of Nafld and Rpah In G/g And G/t + T/t Genotsupporting

confidence: 90%

Contribution of adipoq genetic polymorphism to the formation and course of comorbidity of non-alcoholic fatty liver disease and renoparinchemal arterial hypertension

Babak

Prosolenko

Панченко

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…One of the mechanisms of development of insulin-resistant (IR) states is a dysfunction of the expression of adipose tissue hormones, in particular adiponectin [2,6,9,10].…”

Section: вступmentioning

confidence: 99%

Particularities of Metabolic Indicators in Patients With Arterial Hypertension and Concomitant Obesity Depending on Adiponectin Gene Polymorphism

Kochuieva

Psarova

2019

EUMJ

View full text Add to dashboard Cite

УДК 616.12-008.331.1:613.25:616.43-008.6:575.22 PARTICULARITIES OF METABOLIC INDICATORS IN PATIENTS WITH ARTERIAL HYPERTENSION AND CONCOMITANT OBESITY DEPENDING ON ADIPONECTIN GENE POLYMORPHISM.It is known that ADIPOQ gene has several polymorphic sites, which influence the production and activity of AN. Allelic options of its polymorphic marker G276T are associated with the development of the AO, IR, and diabetes.The aim of the study was to investigate the association of the genetic polymorphism of the G276T marker of the adiponectin gene with changes in metabolic parameters in patients with arterial hypertension (AH) and concomitant obesity.We examined 300 patients with AH 45 to 55 years old who gave informed written consent to participate in the study and met the inclusion criteria. Group 1 consisted of 200 patients with AH and class I-II obesity, group 2 -50 patients with AH and normal body weight, group 3 -50 patients with AH and overweight. The control group consisted of 30 practically healthy individuals, in whom AH and obesity were excluded on the basis of clinical and instrumental examination data.As a result of the study the association of T-allele of the polymorphic marker G276T of the adiponectin gene with the development of comorbidity of AH and obesity was established. It has been proven that adiponectin gene polymorphism influenced changes in metabolic parameters in hypertensive patients with obesity: more pronounced impairment of metabolic parameters in G/T and T/T genotypes as compared to G/G genotype. G/T and T/T genotypes of the polymorphic marker G276T of the adiponectin gene were associated with a significantly higher body mass index, higher triglyceride levels, more pronounced insulin resistance and adipokine imbalance.Relevance. The main component of the metabolic syndrome (MS) is the abdominal obesity (AO) which inevitably leads to insulin resistance (IR). Adiponectin (AN) secreted by the adipocytes protects from the IR development, increases the sensitivity of skeletal muscles to insulin, reduces intake of free fatty acids in a liver and, thus reduces the synthesis of atherogenic lipoproteins. Some investigations prove that the level of the adiponectin in blood plasma correlates back with the mass of the fatty tissue, the waist-hip ratio and IR expressiveness. With obesity, AN secretion decreases, losing its protective role as for the risk of IR development and metabolic violations.

show abstract

“…The etiopathogenesis of primary HT include alterations in the activity of sympathetic nervous system, the renin-angiotensin system, the pathways involved in calcium and sodium homeostasis, the structure and reactivity of the vascular smooth muscle network ( 15 – 17 ). However, both T2D and HT are multigenic diseases where several genetic/epigenetic factors (including genetic polymorphisms) may concur to determine heterogeneous phenotypes ( 18 ). Interestingly, insulin resistance and activation of renin-angiotensin system are frequently observed in obesity with a body-mass index (BMI) > 30.0 kg/m 2 ( 19 , 20 ).…”

Section: Introductionmentioning

confidence: 99%

Hypertension, type 2 diabetes, obesity, and p53 mutations negatively correlate with metastatic colorectal cancer patients’ survival

Ottaiano

Santorsola

Circelli³

et al. 2023

Front. Med.

View full text Add to dashboard Cite

IntroductionWe studied the predictive and prognostic influences of hypertension (HT), type 2 diabetes (T2D), weight, and p53 mutations in metastatic colorectal cancer (CRC) patients.Patients and methodsT2D was diagnosed according to the ADA criteria. HT was classified according to the ACC/AHA guidelines. BMI (body-mass index) was calculated and classified according to the WHO criteria. TruSigt™Oncology 500 kit was applied to construct the genomic libraries for Next Generation Sequencing (NGS) analysis. The Illumina NovaSeq 6000 technological platform and the Illumina TruSight Oncology 500 bioinformatics pipeline were applied to analyze results. Overall survival (OS) was calculated through Kaplan-Meier curves. Univariate and multivariate analyses were performed to assess the relationships between clinical and/or molecular covariates. Associations between HT, T2D, BMI, p53, and clinical variables were evaluated by the χ2 test. P < 0.05 were considered statistically significant.ResultsTwo-hundred-forty-four patients were enrolled. One-hundred-twenty (49.2%), 110 (45.1%), and 50 (20.5%) patients were affected by overweight, HT, and T2D, respectively. DC (disease control) was achieved more frequently in patients without T2D (83.1%) compared to the diabetic ones (16.9%) (P = 0.0246). DC, KRAS mutational status, T2D, BMI, and concomitant presence of T2D, BMI, and HT associated with survival (P < 0.05). At multivariate analysis, age (≥65 vs. <65 years), response to first-line chemotherapy (DC vs. no DC), and concomitant presence of T2D, BMI, and HT (HR: 4.56; 95% CI: 2.40–8.67; P = 0.0217) emerged as independent prognostic variables. P53 was mutated in 31/53 analyzed cases (60.4%). The most frequent gene variants were p.Arg175His and p.Cys135Tyr. High BMI (>25 kg/m2) associated with occurrence of p53 mutations (P < 0.0001). P53 mutated patients presented a worse prognosis compared to the wild-type ones (HR: 3.21; 95% CI: 1.43–7.23; P = 0.0047).ConclusionDiabetic, hypertensive and overweight metastatic CRC patients are a negative prognostic subgroup deserving specific therapeutic strategies. P53 mutations associate with prognosis and BMI unrevealing complex and unexplored connections between metabolism and cancer occurrence.

show abstract

The Role of Genetic Polymorphism in the Formation of Arterial Hypertension, Type 2 Diabetes and their Comorbidity

Cited by 12 publications

References 94 publications

Contribution of adipoq genetic polymorphism to the formation and course of comorbidity of non-alcoholic fatty liver disease and renoparinchemal arterial hypertension

Contribution of adipoq genetic polymorphism to the formation and course of comorbidity of non-alcoholic fatty liver disease and renoparinchemal arterial hypertension

Particularities of Metabolic Indicators in Patients With Arterial Hypertension and Concomitant Obesity Depending on Adiponectin Gene Polymorphism

Hypertension, type 2 diabetes, obesity, and p53 mutations negatively correlate with metastatic colorectal cancer patients’ survival

Contact Info

Product

Resources

About